

BIOCON GROUP

FACT SHEET

December -2012

9M FY 2013 vs. 9M FY 2012

Q3 FY 2013 vs. Q3 FY 2012

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET**

(Rs. Crores)

	December 31, 2012	March 31, 2012
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,445	2,172
	2,545	2,272
Minority interest	5	4
Non-current liabilities		
(a) Long-term borrowings	157	70
(b) Deferred tax liability (net)	36	-
(c) Other long-term liabilities	468	583
(d) Long-term provisions	4	-
	665	653
Current liabilities		
(a) Short-term borrowings	100	187
(b) Trade payables	362	348
(c) Other current liabilities	387	269
(d) Short-term provisions	76	212
	925	1,016
TOTAL	4,140	3,945
ASSETS		
Non-current assets		
(a) Fixed assets	1,720	1,648
(b) Good will on consolidation	12	12
(c) Non-current investments	78	64
(d) Deferred tax asset (net)	-	8
(e) Long term loans and advances	231	185
(f) Other non-current assets	29	29
	2,070	1,946
Current assets		
(a) Current Investments	419	492
(b) Inventories	430	378
(c) Trade receivables	559	492
(d) Cash and cash equivalents	556	523
(e) Short term loans and advances	56	79
(f) Other current assets	50	35
	2,070	1,999
TOTAL	4,140	3,945

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	9M FY 13	9M FY 12	Variance
INCOME			
Biopharmaceuticals	1,143	974	17%
Branded formulations - India	263	195	35%
Total Biopharmaceuticals	1,406	1,169	20%
Contract research	391	292	34%
Total Sales	1,797	1,461	23%
Other income	92	76	20%
Total Revenue	1,889	1,537	23%
EXPENDITURE			
Material & Power Costs	877	682	29%
Staff costs	259	210	24%
Research & Development	121	84	44%
Other Expenses	160	138	16%
Manufacturing, staff & other expenses	1,417	1,114	27%
PBDIT /EBITDA	472	423	11%
Interest and finance charges	7	9	-22%
Depreciation & Amortisation	134	131	2%
PBT	331	283	17%
Taxes	69	42	65%
NET PROFIT FOR THE PERIOD	262	241	9%
Minority Interest	2	-	-
NET PROFIT FOR THE PERIOD, AFTER MINORITY	260	241	8%
EPS Rs.	13.3	12.3	
<i>Note: 1. The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
<i>2. Figures of the Comparative period have been regrouped wherever necessary</i>			
Biopharmaceuticals Income includes:			
Licensing development fees	-	79	
Licensing Income	23	1	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 13	Q3 FY 12	Variance
<u>INCOME</u>			
Biopharmaceuticals	409	335	22%
Branded formulations - India	86	72	19%
Total Biopharmaceuticals	495	407	22%
Contract research	140	110	27%
Total Sales	635	517	23%
Other income	25	19	36%
Total Revenue	660	536	23%
<u>EXPENDITURE</u>			
Material & Power Costs	307	233	32%
Staff costs	88	73	20%
Research & Development	43	33	30%
Other Expenses	55	55	1%
Manufacturing, staff & other expenses	493	394	25%
PBDIT /EBITDA	167	142	18%
Interest and finance charges	3	3	16%
Depreciation & Amortisation	46	43	6%
PBT	118	96	23%
Taxes	25	11	124%
NET PROFIT FOR THE PERIOD	93	85	9%
Minority Interest	1	-	-
NET PROFIT FOR THE PERIOD, AFTER MINORITY	92	85	8%
EPS Rs.	4.7	4.3	
<i>Note: 1. The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
<i>2. Figures of the Comparative period have been regrouped wherever necessary</i>			
<i>Biopharmaceuticals Income includes:</i>			
<i>Licensing development fees</i>	-	31	
<i>Licensing Income</i>	9	-	